Abstract
Evidence supporting the renal benefits of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in elderly patients without proteinuria is lacking. however, until such data are available, if tolerated, these medications should continue to be used in this patient population because of their potent effect on blood pressure.
